The Canadian MPS Society offers Summer Studentship Research Grants to undergraduate students in hopes of fostering future careers in lysosomal storage disorder research.
Our Research Program
The Canadian MPS Society has funded over $1 Million dollars in research with the aim of eventually finding treatments—and, yes, cures—for all types of MPS and related diseases.
Our program now focuses on the new generation of researchers, offering yearly Summer Studentship Research Grants to medical students and undergraduate students across Canada, with the hope that these opportunities may result in more individuals being attracted to research careers involving lysosomal storage disorders.
Summer Studentship Research Grants
These studentships are tenable at any university centre in Canada, and there is no limit on the number of studentships tenable at any given medical centre.
Our research program has been developed with the expert guidance of our Medical Advisory Board in order to ensure continued good stewardship of the funds our donors entrust to us. We issue Requests for Applications (RFAs) annually, and then have our Grant Review Committee – made up up of experienced researchers in the field of MPS – conduct a review which includes scoring and ranking the applications before making final recommendations to our Board of Directors.
Students are expected to spend at least 12 weeks working on their projects, and must submit a formal written report summarizing the results of their research when complete.
Grants of $4,000.00 are payable directly to successful candidates: Students receive initial payments of $2,000.00 and receive an additional $2,000.00 upon research completion and report submission.
Submissions are now closed for 2022.
A Compilation of MPS Funded Research Projects
Read about the MPS funded research projects by past recipients of the Studentship Research Grants.
2021 | Yan Xu Rong | Sainte-Justine Hospital Research Center, Elisa Linton Sanfilippo Research Laboratory | Supervised by Alexey V. Pshezhetsky, Ph.D.
Chaperone Therapy for MPSIIIC
Glucosamine is an inhibitor of HGSNAT that showed promising signs of chaperone effect on the mutant misfolded enzyme in cultured skin fibroblasts of MPSIIIC patients4. Moreover, most recent results from Pshezhetsky lab show that glucosamine partially rescues misfolded mutant HGSNAT and ameliorates pathology on the mouse model of MPSIIIC, expressing HGSNAT with a human misfolding mutation P304L (HgsnatP304L strain). However, the doses of glucosamine used in the mouse study (2 g/kg BW per day) are not achievable in human patients. Therefore, we plan to produce and test derivatives of 2-2-deoxy-glucosamine (GlcNH2) that feature basic, labile, and bulky groups. The goal is to test if the active site of HGSNAT features a binding pocket that is optimized to complex the basic sidechain of its native substrate. These compounds have been already provided to us by our research partners from the University of Alberta.
2021| Alexandra Wyatt |CHU St. Justine | Supervised by Dr. Pshezhetsky
Cathepsin B As a Trigger of β-amyloid Deposition In Neurological Mucopolysaccharidoses
Recent study from the Pshezhetsky lab (11) demonstrated that in the mouse MPS I model, the deposition of amyloid plaques was associated with increased cathepsin B (CATB) activity leading to an alternative pro-amyloidogenic processing of the amyloid precursor protein (APP). Their unpublished data showed that similar pathway exists in the brain of MPS IIIC mice, suggesting a potential role of CATB in the neuropathology of MPS in general.
- Research plan
In order to test the hypothesis that CATB is involved in deposition of amyloid plaques in MPS IIIC mice, the laboratory of Dr. Pshezhetsky generated a double-knockout mouse model (Hgsnat-/-CatB-/-) of MPS IIIC depleted on CATB activity. By themself, the CATB KO mice do not express any pathological phenotype. I will test whether CATB-deficient MPS IIIC mice show amelioration of the disease progression as compared with the original MPS IIIC mice. In particular, I will study their memory by Y-maze and Novel Object Recognition behavioral tests. I will also study the CNS pathology, including neuronal accumulation of Thioflavin-S-positive misfolded protein aggregates, deposition of amyloid plaques and levels of neuroinflammatory GFAP-positive astrocytes and CD11b-positive activated microglia in brain cortex by confocal fluorescent microscopy. Finally, I will directly analyze level of the 16-kDa C-terminal pathogenic APP fragment by Western blots.
The proposed study should confirm existence of a novel CATB-associated alternative amyloidogenic pathway in MPS brain induced by lysosomal storage and potentially leading to neurodegeneration. It also may suggest a novel therapeutic approach for reduction of neurodegeneration and neuroinflammation in MPS by inhibiting CATB activity with small molecule drugs.
2021 | JeaYeon Park |McGill University | Supervised by Dr John Mitchell
Development and Validation of an Extraction Liquid Chromatography Tandem Mass Spectrometry Method To Evaluate the Role of Sphingolipid–1-Phosphate Species in MPSs
Objective and Speciﬁc Aims
As part of our objective to develop methods for comprehensive analysis of sphingolipids in MPS, JeaYeon will develop and validate an extraction – liquid chromatography – tandem mass spectrometry technique to measure and analyse the family of sphingolipid-1-phosphate (C1P, ceramide-1-P and S1P, sphingosine-1-P) species in serum of MPS patients.
In a recent study by Simonaro et.al. (2008), treatment of healthy synovial ﬁbroblasts with GAGs led to production of S1P and showed an increase in cell proliferation, consistent with the hyper plastic synovial tissue in MPS patients. Quebec has a founder eﬀect for Morquio A disease (MPS IV). About 50 patients are followed at the MUHC by Dr John Mitchell, giving us a unique access to clinical samples.
The main objective of this project will be achieved by addressing the following speciﬁc aims
Speciﬁc aim 1 (~4-5 weeks):
To develop tandem mass spectrometry (multiple reaction monitoring) methods to analyse and measure sphingolipid-1-phosphate species on a triple quadrupole MS instrument.
Speciﬁc aim 2 (~2-3 weeks)
To develop extraction methods of sphingolipid-1-phosphate from serum and/or dried blood spots Speciﬁc aim 3 (~4 weeks)
To measure the levels of sphingolipid-1-phosphate species in samples of MPS patients and healthy controls. Identify whether sphingolipid-1-phosphate can be used as a primary clinical biomarker or potential target for MPS disorders.
2021 | Sufyan Rather |The Hospital for Sick Children, Clinical and Metabolic Genetics| Supervised by Dr. Andreas Schulze, MD, PhD, FRCPC
Inhibitory Potential of Class I SRT Candidates in Human Cells Including Neuronal-like Cells
We have identified NDST1 as druggable target for substrate reduction therapy (SRT) of mucopolysaccharidoses, specifically MPS type III (Sanfilippo disorder).
In this project, we will use in vitro assays, to identify lead candidates for the treatment of patients with Sanfilippo disease.
Our class I (gene repressor) SRT candidates were identified by high-content screening of Hek293 cells with an inserted reporter gene. The efficacy of the candidates needs to be confirmed in other human cells including cells resembling human nervous tissues since the regulatory motives necessary for the control of NDST1 expression in these cells may be slightly different. Be2C is a human neuroblastoma cell line whose cell division is under direct control of retinoic acid. LUHMES cells are derived from embryonic human mesencephalon and immortalized by introducing a tetracycline-responsive v-myc gene. They can be easily cultured and maintained, like other cell lines. Both cell lines are well established in our research group.
We will assess the ability of Class I SRT candidates to reduce NDST1 mRNA, protein and enzyme activity with qPCR, western blot and enzyme activity studies in HeLa, Hek293 cells, MPS III A/B/C, and in neuronal-like cell lines Be2C and LUHMES.
2020 | Jenna Thompson |University of Victoria| Supervised by Dr.Francis Choy
CRISPR Based Prime Editing For Correction of MPS Causative
We propose using base and prime editing for correction of causative mutations in MPS diseases. We have designed CRISPR-Cas9 base and prime editing constructs (guide RNA; gRNA) targeting reported patient mutations in ten MPS diseases1. gRNA and either base or prime editors will be delivered to HEK293T cells and analyzed for on-target editing. Editing constructs successful in HEK293T cells will then be tested in patient cells.
2020 | Simon Guindon |CHU Sainte-Justine, Montreal | Supervised by Dr. Philippe Campeau, MD
SLC26A11 Dysfunction in a New Mucopolysaccharide Turnover Disorder
Preliminary data: We studied a patient with the following characteristics: consanguineous parents, microcephaly, intellectual disability, proptosis, hip dysplasia, coxa vara, lordosis, club feet, and significant joint hypermobility at birth. She was given a likely diagnosis of Larsen syndrome at birth, but now at young adult age, the phenotype resembles more Ehlers-Danlos syndrome , musculocontractural type. A mucopolysaccharide biosynthesis defect was suspected on clinical grounds, but panel sequencing of known MPS biosynthesis disease genes was negative. Exome sequencing revealed a homozygous missense in another sulfate transporter, SLC26A11 (Y69C). The mutated residue is highly conserved, and this residue was shown to be critical in plants.3 This protein localizes at the lysosome, where it was proposed to serve as a sulfate exporter.4-6 We have obtained fibroblasts from this patient and stably corrected them with a lentivirus encoding wildtype SLC26A11, using methods we’ve published previously.
Hypothesis and objective: We hypothesize that SLC26A11 dysfunction leads, in cells with a rapid MPS turnover, to sulfate accumulation in lysosomes, and decreased cytoplasmic availability of sulfate essential for MPS synthesis. Our objective is to demonstrate this hypothesis in patient samples and cells.
Our project will allow us to confirm our hypothesis that SLC26A11 mutations cause lysosomal dysfunction and decreased MPS synthesis, and will also allow us to test a potentially new therapy.
2020 | TianMeng Xu |CHU Sainte-Justine, Montreal | Supervised by Dr. Alexey Pshezhetsky
Efficacy of Hematopoietic Stem/Progenitor Cell/LV Gene Transfer in the Mouse Model of Mucopolysaccharidosis III Type C.
The treatment of MPS IIIC is currently not available, however emerging data have shown that Lentivirus (LV)-mediated gene correction of hematopoietic stem/progenitor cells (HSPC) followed by their transplantation provides an efficient method to treat neurological LSDs. Following this idea, we proposed a research program aimed at treating MPSIIIC disease by the supraphysiological delivery of wild-type (WT) HGSNAT to the brain microglia via transplantation of gene-modified HSPC.
Last summer, we tested the efficacy of LV-mediated targeting of the WT HGSNAT cDNA into mouse HSPC cell culture. We showed that LV vectors can be used for the transfer of wild-type HGSNAT gene to mouse HPSC for further transplantation into MPSIIIC mice. Our results indicated that the transduction efficiency of the lentivirus was too low in macrophage culture, we had to modify our protocol to optimize the transduction efficiency of lentiviral vectors. We found that using two hits of lentivirus at MOI 30 within 48 hours yielded better amounts of transduced HSPC than a single hit at MOI 60. This approach was used in our pilot experiment where we transplanted our MPS IIIC mice with HSPC transduced with the lentivirus encoding HGSNAT-GFP enzyme. We found that the engraftment of donor cells in some transplanted MPS IIIC mice was as high as 80%. Furthermore, these mice also showed improved behavior in the open field test and had normalized HGSNAT activity in the bone marrow and spleen, but not in the brain.
The main objective of my summer research project is to improve LV-mediated targeting of the WT HGSNAT cDNA into the brain of our mouse model and to test the efficacy of this lentivirus by carrying out in vivo experiments in a higher number of MPS IIIC KO mouse model.
2019| Camilia Etchart | MUHC | Supervised by Dr. John Mitchell and Dr. Farah El Turk
Analysis Of Serum Cytokine Profile In Mucopolysaccharidoses
This summer research project aims at further characterising the mechanism of GAGs mediated lesions in MPS disorders by examining the levels of pro-inflammatory cytokine and chemokines in the serum of MPS patients.
At the laboratory of Dr John Mitchell, we have unique access to clinical samples from patients at the MUHC and other health centres in Canada. Specific cytokines and chemokines levels in serum of MPSs patients will be quantified using biochemical tools. We will evaluate the levels of TNF-α, IL-1β, IL-6, IL-8, IL-10, MCP-1, MIP-1a and MMP-9 using Quansys (Q-PlexTM) kits. The kit performance is optimised for analysis of precise proteins in human samples. The method provided by this kit is based on ELISA (enzyme-linked immunosorbent assay) concept.
Our ultimate aim is to probe the inter-relationship between serum inflammatory markers (cytokine), the serum level of ceramides (ceramides quantification is part of another project run in our laboratory), and the clinical phenotype.
2019| Orfeo Harrison | MUHC | Supervised by Dr. John Mitchell and Dr. Farah El Turk
Development And Validation of a Robust Dried Blood Spot Ceramide Profiling Method To Study Metabolism In Mucopolysaccharidoses
Last year, we developed a sensitive targeted sphingolipidomics approach to evaluate the ceramide content in serum of MPS patients. The ceramide quantification method employs an electrospray tandem mass spectrometry approach coupled to reverse phase liquid chromatography. Interesting results have been obtained as per the levels of glucosylceramide and dihydroceramide species.
As a continuation of our last year’s project, the objective of this study is to translate the method of ceramide quantification in serum to a method allowing ceramide quantitation in dried blood spots (DBS). Ultimately, we aim to determine how abnormalities of the blood ceramide profile relate to the pathogenesis in MPS disorders, and whether ceramide could be used as a biomarker for diagnosis, follow up and potential therapeutic target.
2018| Afnan Al-Saleh | Montreal Children’s Hospital | Supervised by Dr. John Mitchell
Identification Of Plasma Sphingolipids Biomarkers For Morquio Type A
The research study will be:
Part 1- To develop an extraction procedure (intra-source separation) to purify a specific category of sphingolipids from serum (e.g.: gangliosides, cerebrosides and lactosyl ceramide).
Part 2- To develop initial profiling of various standards of sphingolipids to determine the appropriate MRM pairs used for Liquid Chromatography tandem Mass Spectrometry (LC MS/MS).
Part 3- Ultimately, to quantitate specific plasma sphingolipid biomarkers by LC MS/MS, using internal standard corresponding to the biomarker quantified.
2018| Lauren Wotten | University of Victoria | Supervised by Dr. Francis Choy
Mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B Syndrome): Uptake Of Human Recombinant Naglu Utilizing PTD4-Mediated Transport In MPS IIIB Fibroblasts
The research focus of the Choy lab is to investigate if PTD4, a synthetic derivative of Tat, will facilitate the delivery of recombinant Naglu across BBB thereby improving the bioavailability of recombinant Naglu in the CNS. Previous research in the Choy lab has fused Naglu to PTD4 and stably expressed this fusion construct in Spodoptera frugiperda (Sf9) cells to establish the economical, large-scale production Naglu-PTD4 (7,8).
2018| Iskren Menkovic | Université de Sherbrooke| Supervised by Thérèse Côté-Boileau
Populational MPS Neonatal Screening By MS/MS Using Urine Samples Collected On Filter Paper
We are planning to adapt, optimize and validate the HPLC-MS/MS method using urine samples collected on filter paper to screen all newborns in the province of Quebec for MPSs as part of an evaluative research project.
Different technological steps are involved: 1) Optimize the GAG extraction procedure from the filter paper samples;
2) Develop a robust and rapid ultra-performance liquid chromatography (UPLC) method that allows an adequate separation of HS, DS, CS and creatinine;
3) Optimize a quantitation method using tandem mass spectrometry (MS/MS);
4) Perform a complete validation of the method to ensure that it is robust for a newborn mass screening research project.
Following the validation of the method, we will analyse urine samples collected on filter paper from 21-day old babies to establish reference control values.
Ultimately, we plan to add this new method to the already existing neonatal urine screening program in the province of Quebec as part of an evaluative research endeavour.
Our aim is to detect newborns with MPS as early as possible, and to provide a rapid intervention before the onset of symptoms.